StockNews.AI
CYTK
StockNews.AI
6 hrs

Cytokinetics, Incorporated Sued for Securities Law Violations - Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights – CYTK

1. Cytokinetics faces a class action for misleading NDA timelines. 2. Allegations claim false statements about aficamten's FDA approval process. 3. Investors suffered losses after the truth about the NDA was revealed. 4. Lead plaintiff registration for shareholders is open until November 17, 2025. 5. The firm aims to protect investor rights amid corporate misconduct.

5m saved
Insight
Article

FAQ

Why Bearish?

The allegations indicate potential regulatory delays and investor losses, reflecting negatively on CYTK’s credibility. Historically, similar cases lead to stock declines upon bad news revelations.

How important is it?

The class action lawsuit highlights significant concerns about CYTK’s transparency and business practices affecting investor confidence. Legal disputes often impact stock performance significantly.

Why Short Term?

Negative sentiment and potential stock price declines may occur following disclosures. Immediate investor reactions can create short-term pressures on share prices.

Related Companies

VRTXAMGNPTCT
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=175402&from=3 CLASS PERIOD: December 27, 2023 to May 6, 2025 ALLEGATIONS: According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company’s failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process. On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants’ awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline. As a result of defendants’ false and misleading statements, class members purchased Cytokinetics’ common stock at artificially inflated prices and suffered significant losses when the truth was revealed. DEADLINE: November 17, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=175402&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of CYTK during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 17, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (646) 453-8903

Related News